BACKGROUND: A genetic contribution to cannabis dependence (CaD) has been established but susceptibility genes for CaD remain largely unknown. METHODS: We employed a multistage design to identify genetic variants underlying CaD. We first performed a genome-wide linkage scan for CaD in 384 African American (AA) and 354 European American families ascertained for genetic studies of cocaine and opioid dependence. We then conducted association analysis under the linkage peak, first using data from a genome-wide association study from the Study of Addiction: Genetics and Environment, followed by replication studies of prioritized single nucleotide polymorphisms (SNPs) in independent samples. RESULTS: We identified the strongest linkage evidence with CaD (logarithm of odds = 2.9) on chromosome 8p21.1 in AAs. In the association analysis of the Study of Addiction: Genetics and Environment sample under the linkage peak, we identified one SNP (rs17664708) associated with CaD in both AAs (odds ratio [OR] = 2.93, p = .0022) and European Americans (OR = 1.38, p = .02). This SNP, located at NRG1, a susceptibility gene for schizophrenia, was prioritized for further study. We replicated the association of rs17664708 with CaD in an independent AAs sample (OR = 2.81, p = .0068). The joint analysis of the two AA samples demonstrated highly significant association between rs17664708 and CaD with adjustment for either global (p = .00044) or local ancestry (p = .00075). CONCLUSIONS: Our study shows that NRG1 is probably a susceptibility gene for CaD, based on convergent evidence of linkage and replicated associations in two independent AA samples.
BACKGROUND: A genetic contribution to cannabis dependence (CaD) has been established but susceptibility genes for CaD remain largely unknown. METHODS: We employed a multistage design to identify genetic variants underlying CaD. We first performed a genome-wide linkage scan for CaD in 384 African American (AA) and 354 European American families ascertained for genetic studies of cocaine and opioid dependence. We then conducted association analysis under the linkage peak, first using data from a genome-wide association study from the Study of Addiction: Genetics and Environment, followed by replication studies of prioritized single nucleotide polymorphisms (SNPs) in independent samples. RESULTS: We identified the strongest linkage evidence with CaD (logarithm of odds = 2.9) on chromosome 8p21.1 in AAs. In the association analysis of the Study of Addiction: Genetics and Environment sample under the linkage peak, we identified one SNP (rs17664708) associated with CaD in both AAs (odds ratio [OR] = 2.93, p = .0022) and European Americans (OR = 1.38, p = .02). This SNP, located at NRG1, a susceptibility gene for schizophrenia, was prioritized for further study. We replicated the association of rs17664708 with CaD in an independent AAs sample (OR = 2.81, p = .0068). The joint analysis of the two AA samples demonstrated highly significant association between rs17664708 and CaD with adjustment for either global (p = .00044) or local ancestry (p = .00075). CONCLUSIONS: Our study shows that NRG1 is probably a susceptibility gene for CaD, based on convergent evidence of linkage and replicated associations in two independent AA samples.
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Joel Gelernter; Carolien Panhuysen; Roger Weiss; Kathleen Brady; Victor Hesselbrock; Bruce Rounsaville; James Poling; Marsha Wilcox; Lindsay Farrer; Henry R Kranzler Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2005-07-05 Impact factor: 3.568
Authors: Pingxing Xie; Henry R Kranzler; Michael Krauthammer; Kelly P Cosgrove; David Oslin; Raymond F Anton; Lindsay A Farrer; Marina R Picciotto; John H Krystal; Hongyu Zhao; Joel Gelernter Journal: Biol Psychiatry Date: 2011-06-17 Impact factor: 13.382
Authors: Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis Journal: Lancet Date: 2007-07-28 Impact factor: 79.321
Authors: Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams Journal: Neurosci Biobehav Rev Date: 2016-09-14 Impact factor: 8.989
Authors: Tariq W Chohan; Aurelie A Boucher; Jarrah R Spencer; Mustafa S Kassem; Areeg A Hamdi; Tim Karl; Sandra Y Fok; Maxwell R Bennett; Jonathon C Arnold Journal: Schizophr Bull Date: 2014-01-17 Impact factor: 9.306
Authors: Joel Gelernter; Henry R Kranzler; Richard Sherva; Ryan Koesterer; Laura Almasy; Hongyu Zhao; Lindsay A Farrer Journal: Biol Psychiatry Date: 2013-10-19 Impact factor: 13.382
Authors: Karen Hodgson; Laura Almasy; Emma E M Knowles; Jack W Kent; Joanne E Curran; Thomas D Dyer; Harald H H Göring; Rene L Olvera; Mary D Woolsey; Ravi Duggirala; Peter T Fox; John Blangero; David C Glahn Journal: Addiction Date: 2016-09-26 Impact factor: 6.526
Authors: Scott Mackey; Kees-Jan Kan; Bader Chaarani; Nelly Alia-Klein; Albert Batalla; Samantha Brooks; Janna Cousijn; Alain Dagher; Michiel de Ruiter; Sylvane Desrivieres; Sarah W Feldstein Ewing; Rita Z Goldstein; Anna E Goudriaan; Mary M Heitzeg; Kent Hutchison; Chiang-Shan R Li; Edythe D London; Valentina Lorenzetti; Maartje Luijten; Rocio Martin-Santos; Angelica M Morales; Martin P Paulus; Tomas Paus; Godfrey Pearlson; Renée Schluter; Reza Momenan; Lianne Schmaal; Gunter Schumann; Rajita Sinha; Zsuzsika Sjoerds; Dan J Stein; Elliot A Stein; Nadia Solowij; Susan Tapert; Anne Uhlmann; Dick Veltman; Ruth van Holst; Henrik Walter; Margaret J Wright; Murat Yucel; Deborah Yurgelun-Todd; Derrek P Hibar; Neda Jahanshad; Paul M Thompson; David C Glahn; Hugh Garavan; Patricia Conrod Journal: Prog Brain Res Date: 2015-11-04 Impact factor: 2.453
Authors: Jarrah R Spencer; Keturah M E Darbyshire; Aurelie A Boucher; Mohammed A Kashem; Leonora E Long; Iain S McGregor; Tim Karl; Jonathon C Arnold Journal: Front Cell Neurosci Date: 2013-02-26 Impact factor: 5.505